Literature DB >> 7915237

The long-term effects of metoprolol and epanolol on tissue-type plasminogen activator and plasminogen activator inhibitor 1 in patients with ischaemic heart disease.

R A Wright1, A M Perrie, F Stenhouse, K G Alberti, R A Riemersma, I R MacGregor, N A Boon.   

Abstract

This double-blind, randomized parallel group study investigated the effect of 6 months beta-adrenoceptor antagonist therapy with either metoprolol (beta 1-selective without intrinsic sympathomimetic activity [ISA]) or epanolol (beta 1-selective with ISA) on markers of endogenous fibrinolysis in 20 patients with chronic stable angina receiving concurrent treatment with nifedipine. Neither drug had an effect on tissue-type plasminogen activator or plasminogen activator inhibitor type 1 (PAI-1). A significant correlation between fasting insulin and PAI-1 has previously been described and was confirmed in this study. The group treated with metoprolol showed a significant rise in fasting insulin after 6 months with no change in PAI-1. This suggests that the previously described link between these two may not be causal.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7915237     DOI: 10.1007/bf00192563

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

Review 1.  Recent studies on the effects of beta blockers on blood lipid levels.

Authors:  W C Roberts
Journal:  Am Heart J       Date:  1989-03       Impact factor: 4.749

2.  Critical variables in the radioimmunoassay of serum insulin using the double antibody technic.

Authors:  J S Soeldner; D Slone
Journal:  Diabetes       Date:  1965-12       Impact factor: 9.461

3.  Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients.

Authors:  T Pollare; H Lithell; I Selinus; C Berne
Journal:  BMJ       Date:  1989-04-29

4.  Plasminogen activator inhibitor (PAI-1) in plasma and platelets.

Authors:  N A Booth; A J Simpson; A Croll; B Bennett; I R MacGregor
Journal:  Br J Haematol       Date:  1988-11       Impact factor: 6.998

5.  Interaction study between nifedipine and recombinant tissue-type plasminogen activator in healthy subjects.

Authors:  A De Boer; C Kluft; F J Kasper; J M Kroon; H C Schoemaker; D D Breimer; P A Soons; A F Cohen
Journal:  Br J Clin Pharmacol       Date:  1993-08       Impact factor: 4.335

6.  Endogenous tissue-type plasminogen activator and risk of myocardial infarction.

Authors:  P M Ridker; D E Vaughan; M J Stampfer; J E Manson; C H Hennekens
Journal:  Lancet       Date:  1993-05-08       Impact factor: 79.321

7.  Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction.

Authors:  A Hamsten; U de Faire; G Walldius; G Dahlén; A Szamosi; C Landou; M Blombäck; B Wiman
Journal:  Lancet       Date:  1987-07-04       Impact factor: 79.321

8.  Effects of selective (beta-1 and beta-2) and nonselective beta adrenoceptor antagonists on the cardiovascular and metabolic responses to isoproterenol: comparison with ICI 141,292.

Authors:  H J Smith; S E Halliday; D C Earl; D Stribling
Journal:  J Pharmacol Exp Ther       Date:  1983-07       Impact factor: 4.030

9.  Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.

Authors:  A Hamsten; B Wiman; U de Faire; M Blombäck
Journal:  N Engl J Med       Date:  1985-12-19       Impact factor: 91.245

10.  Effects of nadolol on hemodynamic and hemostatic responses to potential mental and physical triggers of myocardial infarction in subjects with mild systemic hypertension.

Authors:  A H Jimenez; G H Tofler; X Chen; M E Stubbs; H S Solomon; J E Muller
Journal:  Am J Cardiol       Date:  1993-07-01       Impact factor: 2.778

View more
  1 in total

1.  Effect of benazepril amlodipine combination on fibrinolysis in hypertensive diabetic patients.

Authors:  Roberto Fogari; Paola Preti; Pierangelo Lazzari; Luca Corradi; Annalisa Zoppi; Elena Fogari; Amedeo Mugellini
Journal:  Eur J Clin Pharmacol       Date:  2003-06-27       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.